Core Insights - Purple Biotech has announced a collaboration with Converge Bio to enhance its tri-specific antibody platform using generative AI for oncology applications [1][3] - The collaboration aims to accelerate drug discovery timelines and improve the quality of therapeutic candidates targeting solid tumors [1][4] Company Overview - Purple Biotech is a clinical-stage company focused on developing next-generation immunotherapy platforms that maximize anti-cancer potency while minimizing toxicity [9] - The company's lead program, CAPTN-3, involves masked tri-specific antibodies that engage both T cells and NK cells, enhancing therapeutic efficacy [8][9] Collaboration Details - The partnership will leverage Converge Bio's AI platform, which integrates large-scale biological data with predictive modeling to optimize antibody candidates [3][5] - This collaboration is expected to expand Purple Biotech's pipeline with high-quality candidates while reducing development timelines [4][6] Technology and Innovation - The CAPTN-3 platform utilizes proprietary capping technology to confine immune activation to the tumor microenvironment, significantly improving the therapeutic window compared to traditional T-cell engagers [8][9] - The collaboration aims to develop novel T cell engagers that combine optimal functional properties with favorable physicochemical characteristics [3][4] Strategic Goals - The integration of AI into Purple Biotech's development strategy positions the company at the forefront of innovation in multi-specific antibody therapies [3][5] - The collaboration is seen as a strategic expansion to address additional high-value oncology targets and resistance mechanisms [6]

Core Viewpoint - Purple Biotech Ltd. has regained compliance with Nasdaq's minimum bid price requirement, allowing for continued listing on the Nasdaq Capital Market [2]. Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing a next-generation immunotherapy platform aimed at maximizing anti-cancer potency while minimizing toxicity [3]. - The company is advancing its lead program, CAPTN-3, which utilizes masked tri-specific antibodies to target tumors and engage T cells and NK cells [3]. - The lead candidate, IM1240, is progressing towards clinical trials, while the second candidate, IM1305, is in preclinical development [3]. - The pipeline includes additional clinical-stage assets such as CM24, a CEACAM1-blocking antibody, and NT219, a dual IRS1/2 and STAT3 inhibitor, both of which are in Phase 2 studies for various cancers [3].

Company Leadership Transition - Gil Efron will step down as CEO of Purple Biotech Ltd. effective August 2026 due to health considerations, but will continue to lead corporate development and remain on the Board of Directors [1][2] - The Board of Directors has initiated a search for a new CEO with experience in leading innovative biotechnology companies [2][3] - Efron has served in senior leadership roles for eight years, including as CFO and CEO, and has been instrumental in the company's strategic repositioning around the CAPTN-3 platform [3][4] CAPTN-3 Platform Overview - CAPTN-3 is Purple Biotech's lead program, featuring capped tri-specific antibodies that target tumor-associated antigens while engaging T cells and NK cells [4][5] - The proprietary capping technology confines immune activation to the tumor microenvironment, significantly expanding the therapeutic window compared to conventional T-cell engagers [4][5] - The lead candidates, IM1240 and IM1305, are in preclinical development, with IM1240 advancing toward clinical trials [5][6] Company Background - Purple Biotech Ltd. is a clinical-stage company focused on developing next-generation immunotherapy platforms aimed at maximizing anti-cancer potency while minimizing toxicity [5][6] - The company is headquartered in Rehovot, Israel, and is advancing its lead program, CAPTN-3, alongside additional clinical-stage assets [6]

Core Insights - The company is focusing on the development of tri-specific antibodies from the CAPTN-3 platform, specifically IM1240 and IM1305, targeting tumor-associated antigens 5T4 and TROP2 respectively [1][2] - Positive preclinical data indicates multi-arm anti-tumor activity for both IM1240 and IM1305, with an expanded therapeutic window and commercially viable yield achieved for IM1240 [1][3] - The company reported a total cash position of $9.5 million as of December 31, 2025, which is expected to provide operational runway into 2027 [1][13] Development Highlights - The CAPTN-3 platform has shown significant and sustained tumor regression across IM1240 and IM1305, with transcriptomic analysis supporting the inclusion of the NKG2A arm in designs [6][7] - IM1240 demonstrated improved tolerability in toxicology studies, with doses up to 300-fold higher than a non-capped comparator, and significantly reduced immune-related toxicity [6] - Manufacturing milestones for IM1240 have been achieved, positioning the program competitively for future development [5] Financial Performance - For the three months ended December 31, 2025, research and development expenses increased to $1.8 million from $0.5 million in the same period of 2024, primarily due to CAPTN-3 platform development activities [8] - General and administrative expenses rose to $1.1 million compared to $0.6 million in the same period of 2024, attributed to increased professional services fees [9] - The company recognized a $20.5 million impairment loss related to in-process research and development assets CM24 and NT219, reflecting a strategic focus on the CAPTN-3 platform [10][15] Loss and Cash Flow - The operating loss for the year ended December 31, 2025, was $27.5 million, an increase from $11 million in 2024, primarily due to the impairment expenses [16] - The net loss for the year was $26.4 million, or $54.9 loss per basic ADS, compared to a net loss of $7.2 million in 2024 [17] - Cash and cash equivalents at the end of 2025 were $8.7 million, up from $7.4 million at the end of 2024, indicating a net increase in cash flow [30]

Core Viewpoint - Purple Biotech Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares to regain compliance with Nasdaq's minimum bid price requirement, effective March 2, 2026 [1][2]. Group 1: ADS Ratio Change - The ADS Ratio will change from 1 ADS representing 200 ordinary shares to 1 ADS representing 2,000 ordinary shares, effectively a one-for-ten reverse ADS split [1][2]. - Registered holders of certificated ADSs must surrender their ADSs for cancellation to receive new ADSs, while holders of uncertificated ADSs will have their ADSs automatically exchanged [2]. - The new CUSIP number assigned due to the ADS Ratio Change is 74638P307, and the ADSs will continue to trade under the symbol "PPBT" on Nasdaq [2]. Group 2: Impact on Trading - The ADS trading price is expected to increase proportionally as a result of the ADS Ratio Change, enhancing its suitability for trading on Nasdaq [4]. - There is no assurance that the ADS trading price post-change will be equal to or greater than ten times the price before the change [4]. Group 3: Company Overview - Purple Biotech is a clinical-stage oncology company focused on developing therapies to overcome tumor immune evasion and drug resistance [5]. - The lead program, CAPTN-3, involves capped tri-specific antibodies targeting tumors while engaging T cells and NK cells, with candidates IM1240 and IM1305 in various stages of development [5]. - The pipeline includes clinical-stage assets like CM24 and NT219, targeting specific cancer types with promising outcomes in clinical studies [5].

Core Insights - The CAPTN-3 platform by Purple Biotech demonstrates significant tumor regression through two tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens [1][2] - The NKG2A arm is crucial for enhancing the anti-cancer immune activity of IM1240, particularly in PD1-resistant patient-derived explants [1][3] Group 1: CAPTN-3 Platform and Antibodies - The CAPTN-3 platform combines T-cell engagement, NKG2A-mediated immune activation, and tumor-antigen targeting into a single tri-specific molecule, showing potential for a synergistic immune response [2][3] - IM1240 has shown strong anti-tumor activity in PD1-resistant models, indicating its effectiveness even in previously resistant tumors [4][6] - IM1305, targeting TROP2, demonstrates high-affinity binding and potent tumor cell killing across various cancer types, reinforcing the platform's versatility [9] Group 2: Preclinical Data and Findings - New preclinical data presented at the ESMO Immuno-Oncology Congress 2025 highlights the anti-tumor activity of IM1240 in models resistant to PD1 therapy [1][2] - Transcriptomic analysis of approximately 11,000 TCGA samples indicates a strong association between NKG2A expression and tumor expression of 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs [1][6] - IM1305 induced sustained tumor regression in humanized triple-negative breast cancer mouse models at low doses, demonstrating broad application potential [7]

Core Insights - Purple Biotech Ltd. has initiated the development of a second tri-specific antibody, IM1305, targeting TROP2, and achieved a manufacturing milestone for its first tri-specific antibody, IM1240, which targets 5T4 [1][4] - The company reported a cash position of $10.5 million as of September 30, 2025, with an expected cash runway into the first half of 2027, supporting the development of its CAPTN-3 technology platform [1][10] Financial Performance - Research and Development Expenses for the three months ended September 30, 2025, were $0.6 million, a decrease of 56.4% from $1.3 million in the same period of 2024, primarily due to reduced costs associated with the CM24 Phase 2 study [5] - General and Administrative Expenses remained consistent at $0.8 million for the three months ended September 30, 2025, compared to the same period in 2024 [6] - The Operating Loss for the three months ended September 30, 2025, was $1.4 million, a decrease of 35.8% from $2.1 million in the same period of 2024 [6] - The Net Loss for the three months ended September 30, 2025, was $1.3 million, or $0.29 per basic and diluted ADS, compared to a net loss of $0.7 million, or $0.39 per basic and diluted ADS, in the same period of 2024 [9] Clinical and Corporate Developments - The company plans to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND), and initiate a Phase 1 study for IM1240 in 2026 [2] - IM1240 has demonstrated tumor cell death in patient-derived, treatment-resistant head and neck biopsies, advancing toward first-in-human clinical trials [4] - The CM24 Phase 2 study will utilize identified biomarkers for patient selection in the upcoming Phase 2b study, which is subject to partnering [4] Patent and Intellectual Property - Purple Biotech received an intention to grant a European patent covering NT219 combinations with immunotherapies or MEK inhibitors to overcome tumor resistance [3][5]

Core Points - Purple Biotech Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as the closing bid price for its American Depositary Shares (ADSs) has been below $1.00 for 30 consecutive trading days [1] - The company has a 180-day period until April 14, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for at least ten consecutive business days [2] - The notification does not affect the company's current Nasdaq listing or trading of its ADSs, which will continue under the symbol "PPBT" [3] Compliance and Remediation - If compliance is not regained by April 14, 2026, the company may be eligible for an additional 180 days to cure the deficiency, provided it meets other listing requirements [4] - The company intends to monitor its ADS closing bid price and may consider options to regain compliance, including potentially changing the ADS to ordinary shares ratio [5] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [6] - CAPTN-3 is a preclinical platform utilizing tri-specific antibodies to enhance immune response within the tumor microenvironment, while CM24 is a humanized monoclonal antibody targeting CEACAM1 to block tumor immune evasion [6][7] - NT219 is a novel small molecule that targets IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab in clinical studies [7]

Core Viewpoint - Purple Biotech Ltd. is advancing its clinical-stage therapies, particularly NT219, which targets tumor immune evasion and drug resistance, and has received an intention to grant a European Patent for its combination therapies [1][2][3] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes NT219, CAPTN-3, and CM24 [4] - The company is headquartered in Rehovot, Israel, and is publicly traded on NASDAQ and TASE under the ticker PPBT [4] Patent and Intellectual Property - The European Patent Office intends to grant a patent for NT219 combinations with leading immunotherapies, which could provide broad protection until 2036 [2] - The patent covers combinations of NT219 with various immunotherapies and chemotherapies, aimed at enhancing treatment sensitivity for resistant tumors [2] Clinical Development - A Phase 2 study for NT219 in combination with immunotherapy is underway, specifically targeting squamous cell carcinoma of the head and neck [3][5] - The study evaluates NT219 with pembrolizumab and cetuximab, building on previous Phase 1 results that showed anti-tumor activity [3][5] - Preclinical data supports the synergistic effects of NT219 with immunotherapy, indicating a shift in the tumor microenvironment from immunosuppressive to immunoreactive [3] Therapeutic Mechanism - NT219 functions as a dual inhibitor targeting IRS1/2 and STAT3, both of which are critical in drug resistance and tumor immune evasion [3][5] - The company is also developing CAPTN-3, a platform of tri-specific antibodies designed to enhance immune response within the tumor microenvironment [4]

Core Insights - Purple Biotech is advancing the development of a tri-specific antibody targeting TROP2, which is part of its CAPTN-3 platform aimed at overcoming tumor immune evasion and drug resistance [1][2][8] - The company plans to submit an Investigational New Drug (IND) application for its first CAPTN-3 tri-specific antibody, IM1240, in 2026 [1] - Encouraging preclinical results have shown sustained tumor regression in human triple negative breast cancer (TNBC) models, with significant cell death in various tumor types at low doses [4][5] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance [8] - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [8][9] - The CAPTN-3 platform utilizes a unique mechanism of action that engages both innate and adaptive immune systems to enhance anti-tumoral responses [8] Technology and Mechanism - The tri-specific antibody IM1305 includes a masked anti-CD3 arm designed to reduce off-target effects while enhancing efficacy in the tumor microenvironment [3][6] - TROP2 is expressed in various solid tumors and is linked to poor prognosis, making it a significant target for therapeutic development [5][6] - The CAPTN-3 platform's ability to recruit multiple immune effectors (T and NK cells) is expected to provide a strong rationale for its effectiveness across diverse tumor types [6][7] Future Prospects - The company is optimistic about the growing interest in TROP2 as a therapeutic target and aims to leverage its technological advancements to accelerate development timelines [7] - Purple Biotech believes that its CAPTN-3 platform can generate multiple programs and expand partnership opportunities in the oncology space [7]